{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/05/01/3285832/0/en/MapLight-Therapeutics-Announces-Completion-of-Enrollment-in-ZEPHYR-Phase-2-Trial-and-Updates-Expected-Timing-of-Topline-Results.html", "message": "News view counter 696803 successfully enlarged"}